PHILIP BIBB: Open Payments
NPI 1598827180 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 20 payments from 12 companies in 2025. Trend: 2023 $113 · 2024 $169 · 2025 $510
Food & beverage: $510
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 1 | $145 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Amgen Inc. | 3 | $48 |
| Novo Nordisk Inc | 2 | $46 |
| PFIZER INC. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Zimmer Biomet Holdings, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
| ABIOMED | 1 | $19 |
Products named: IQIRVO, REXULTI, OTEZLA, PAXLOVID, CAPLYTA, Ozempic, OPSUMIT, mymobility Platform.
Industry payments across NC — which companies pay providers there.
